Date: Thu, 18 Dec 1997 18:19:43 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4927
Last-modified: Mon, 06 Oct 1997 21:48:17 GMT

<HTML>
<HEAD>
<TITLE>1996 Neoprobe Highlights</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">
<H2><FONT COLOR="PURPLE" FACE="MS Sans Serif"><FONT><BR>
</FONT></FONT></H2>

<TABLE BORDER="0" ALIGN="DEFAULT" WIDTH="100%">
<TR>
<TD VALIGN="TOP" WIDTH="25%" COLSPAN="3">
<H1><B><FONT COLOR="Purple">1996 highlights</FONT></B></H1>
</TD>
</TR>
<TR>
<TD VALIGN="TOP" WIDTH="25%" COLSPAN="3">
<P>	<I><B><FONT COLOR="Purple">* January</FONT></B></I><B></B></P>
<P>	Acquired exclusive rights to XTL Biopharmaceutical's Trimera<SUP><FONT SIZE="-2">XTL</FONT></SUP> technology for developing ACT therapies and human monoclonal antibodies.</P>
<P>	<I><B><FONT COLOR="Purple">* March</FONT></B></I></P>
<B><I><FONT COLOR="Purple"></FONT></I></B>
<P>	Initial RIGScan<SUP><FONT SIZE="-2">&reg;</FONT></SUP> CR49 results of pivotal multicenter trials reported at the Society of Surgical Oncology's annual meeting, showing that the RIGS procedure helped surgeons find additional cancer in a significant number of patients.</P>
<P>	<I><B><FONT COLOR="Purple">* April</FONT></B></I><B></B></P>
<P>	Completed a successful $32.4 million public offering involving the sale of 1.75 million shares of Neoprobe common stock.</P>
<P>	Formed a joint venture with Peptor Ltd. to develop radiolabeled, small, stable peptide analogs as cancer detection and treatment products.</P>
<P>	<I><B><FONT COLOR="Purple">* May</FONT></B></I><B></B></P>
<P>	Patent granted to National Cancer Institute and University of Nebraska Medical Center researchers covering a large group of second-generation monoclonal antibodies, including the CC49 component of Neoprobe's lead product, RIGScan CR49.</P>
<P>	Secured licenses to a portfolio of 120 patents from The Dow Chemical Company covering chelation technology and radioimmunotherapy.</P>
<P>	Filed Neoprobe's first marketing application, or &quot;dossier,&quot; for RIGScan CR49 to the European regulatory authorities.</P>
<P>	<I><B><FONT COLOR="Purple">* June</FONT></B></I><B></B></P>
<P>	Entered into an agreement to use the cGMP cell processing facilities of Cellcor for RIGS/ACT<SUP><FONT SIZE="-2">TM</FONT></SUP>. </P>
<P>	<I><B><FONT COLOR="Purple">* July</FONT></B></I><B></B></P>
<P>	Dossier accepted for review by European regulatory authorities, one of the first of its kind reviewed under the new centralized European Union procedures.</P>



<P>	<B><I><FONT COLOR="Purple">* August</FONT></I></B></P>
<P>Acquired from Biomira Inc. an exclusive worldwide license for use of Biomira's MAb-170 for the surgical detection of breast cancer and options to additional antibodies.</P>
<P>Coordinated a RIGS technology and lymphatic mapping symposium at the 8th Congress of the European Society of Surgical Oncology in Dublin, Ireland.</P>
<P><B><I><FONT COLOR="Purple">* September</FONT></I></B></P>
<P>Signed a unique agreement with United States Surgical Corporation for marketing RIGS surgical cancer detection products.</P>
<P><B><I><FONT COLOR="Purple">* October</FONT></I></B></P>
<P>Cancer researcher John Daly, M.D., Cornell University Medical Center, New York Hospital, presented Phase III data for RIGScan CR49 at the American College of Surgeons annual meeting.</P>
<P>	<I><B><FONT COLOR="Purple">*	November</FONT></B></I><B></B></P>
<P>Completed enrollment and participation of 287 patients in a Phase III trial for RIGScan CR49 for primary colorectal cancer.</P>
<P>Garnered approximately $15 million from the exercise of over 99% of 2,330,000 Series E warrants which expired November 12.</P>
<P>Announced beginning of a multiphase initiative for breast cancer diagnosis and treatment, opening a Phase I study for RIGS surgical detection and a pilot study for activated cellular therapy and supporting intraoperative lymphatic mapping research with use of the Neoprobe<SUP><FONT SIZE="-2">&reg;</FONT></SUP> 1000 device.</P>
<P><B><I><FONT COLOR="Purple">* December</FONT></I></B></P>
<P>Submitted the company's first Biologics License Application (BLA) to the United States FDA for RIGScan CR49.</P>
<P><B><I><FONT COLOR="Purple">* January 1997</FONT></I></B></P>
<P>Received marketing approval in South Korea for RIGScan CR49.</P>
</TD>
</TR>
</TABLE>

<CENTER><TABLE ALIGN="center">
	
<TR>
	
<TD><A HREF="mission.htm"><IMG WIDTH="50" HEIGHT="27" SRC="../../images/left-arrow.gif" BORDER="0"></A></TD>
<TD><A HREF="pyramidpg.htm"><IMG WIDTH="81" HEIGHT="20" SRC="../../images/index-button.gif" BORDER="0"></A><BR>
<A HREF="../../index.html"><IMG WIDTH="81" HEIGHT="21" SRC="../../images/home-button.gif" BORDER="0"></A>


















</TD>
<TD><A HREF="pg2.00.htm"><IMG WIDTH="50" HEIGHT="27" SRC="../../images/right-arrow.gif" BORDER="0"></A></TD>
	</TR>
</TABLE></CENTER>

<P><IMG WIDTH="1" HEIGHT="1" SRC="../../images/optimizing.gif"><IMG WIDTH="1" HEIGHT="1" SRC="../../images/bill.jpg"></P>

</BODY>
</HTML>